Should PAR revive the inhaled PPS formulation?, page-4

I think it's definitely worth investigating further and will also help PAR revive its inhaled PPS formulation, which has always been of interest to PR. I'm not convinced iPPS will lead to meaningful changes for ARDs patients, but based on the results obtained for heparin, it is probable the inhaled PPS formulation may help ARDs patients.

In terms of costings, PAR already has a wealth of information from previous work done with hayfever (preclinical studies, clinical trials, R&D) so will be able to leverage this information for any future studies. They can also enter into a partnership with a research group and obtain funding from govt sources to fund a clinical trial. But any initial trial will only need to be small i.e. 20-30 patients and can be exploratory or open label to keep initial costs low.